KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Return on Capital Employed: 2019-2024

Historic Return on Capital Employed for Esperion Therapeutics (ESPR) over the last 6 years, with Dec 2024 value amounting to 1.90%.

  • Esperion Therapeutics' Return on Capital Employed rose 834.00% to 8.44% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.44%, marking a year-over-year increase of 834.00%. This contributed to the annual value of 1.90% for FY2024, which is 411.00% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Return on Capital Employed of 1.90% as of FY2024, which was up 186.45% from -2.20% recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Return on Capital Employed registered a high of 1.90% during FY2024, and its lowest value of -2.20% during FY2023.
  • Moreover, its 3-year median value for Return on Capital Employed was -0.81% (2022), whereas its average is -0.37%.
  • As far as peak fluctuations go, Esperion Therapeutics' Return on Capital Employed slumped by 140bps in 2023, and later spiked by 411bps in 2024.
  • Esperion Therapeutics' Return on Capital Employed (Yearly) stood at -0.64% in 2020, then decreased by 13bps to -0.77% in 2021, then declined by 4bps to -0.81% in 2022, then crashed by 140bps to -2.20% in 2023, then soared by 411bps to 1.90% in 2024.